Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates

The shares of health insurers in the U.S. recorded gains after the Trump administration announced 2027 payment rate increases for Medicare Advantage that were higher than what had been proposed back in January. That improved rate would increase payments to these firms by about $13bn in the coming fiscal year 2027. 

In January when the federal government revealed that it would be increasing these payments by 0.09%, the insurance firms took a hit to their stock prices because this rate was much lower than had been expected. Investors viewed that small increase as additional pressure on already tight margins, but the surprise announcement of about 2.8% extra payments to MA firms covering older adults lifted spirits. 

After the Tuesday announcement, UnitedHealth stock jumped by at least 10%, Humana rallied by 8%, CVS Health saw gains of approximately 7% while Elevance Health recorded a 3% rally. 

Expectations on Wall Street were that payment rates would be increased by 1% and the bigger rate announced creates hope that MA firms would experience some margin growth in the coming year. The investment appeal of these companies has also improved, according to Whit Mayo, an analyst at Leerink. 

Health insurance firms had said the low rate suggested in January didn’t reflect the realities on the ground characterized by rising costs of providing medical care. These rising costs had increasingly squeezed company margins over the previous three years and firms were disappointed that the government wasn’t factoring those higher costs into its calculations while determining the rate at which to bump up MA insurer payments. 

With this increase, companies have been given some breathing room to improve their margins. The rate increase also dampens the thinking that the federal government was becoming more hostile to the health insurance industry. 

Additional good news was provided by the revelation that companies providing MA policies would get an additional increase of 2.5% due to the changes being made in how health status risks are assessed. This brings the total rate increase to approximately 5%. It remains to be seen whether the share price rally will last or reverse over the coming weeks and months. 

For now, MA coverage providers like Astiva Health that have been grappling with a variety of challenging operational conditions now have something positive to look forward to as they continue to serve the underserved communities like racial minorities they have chosen to focus on as their mission in the jurisdictions where they have operations. 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN